Healthcare Business

road fork sign

Has Biocept Reached An Inflection Point?

Biocept, Inc. (NASDAQ: BIOC) has seen its stock move up over 200% in the past week, only to give back about 20% in Thursday's trading. This initial jump was brought about when Biocept ...
Read Full Story »
health care

5 Health Care Stocks That Are Possible Buyout Candidates

One great way for companies to expand growth, earnings and product offerings beyond internal organic expansion is to go the takeover route. While sometimes it can prove to be dilutive, ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Comfortable hospital bed

Top UBS Health Care Stocks to Buy for 2015 and Beyond

As the market surges higher, investors start to get a touch more concerned about where they allocate capital. One sector that is consistently ranked as an overweight from almost every ...
Read Full Story »
135093244

Steep Discount on Health Care REIT Secondary Offering

Health Care REIT Inc. (NYSE: HCN) has priced its underwritten public secondary offering of 17 million shares of its common stock at a price of $75.50 per share. While it ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »
Exercise fitness

Biocept Breaks Through With Columbia Study

Biocept Inc. (NASDAQ: BIOC) announced that its blood-based diagnostic, OncoCEE-BR, was used to determine hormonal status of metastatic breast cancer patients in a prospective study at Columbia University in New ...
Read Full Story »
DNA

Is Rigel Getting Enough From Bristol-Meyers?

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Bristol-Myers Squibb Co. (NYSE: BMY) announced Monday morning that they have entered into a collaboration agreement regarding the development and commercialization of cancer immunotherapies. ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
research

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene Corp. (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid in conjunction with dexamethasone. This would go toward treating patients that ...
Read Full Story »
Pills

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has announced that it will have another public offering of its common stock. The total offering is expected to raise an aggregate of roughly $225 ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Pills

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) received a favorable rating from Merrill Lynch, and as a result the stock was climbing in Tuesday’s trading session. The firm raised its rating to ...
Read Full Story »
surgeons

The Driving Force Behind Medtronic Earnings

Tuesday before the markets opened, Medtronic PLC (NYSE: MDT) reported its fiscal third-quarter financial results as $1.01 in earnings per share (EPS) on $4.3 billion in revenue. That was against ...
Read Full Story »
145922793

What to Expect From Medtronic Earnings

Medical device maker Medtronic PLC (NYSE: MDT) is scheduled to report its fiscal third-quarter results Tuesday before the opening bell. Thomson Reuters has consensus estimates of $0.97 in earnings per ...
Read Full Story »